drugset
drugset / Trial / NCT02440035

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 in Healthy Adult Participants

NCT02440035 ↗

Phase 1 Completed 48 enrolled Crucell Holland BV
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to assess the safety and tolerability of intramuscular homologous and heterologous prime-boost regimens of Ad35.RSV.FA2 (human adenovirus-vectored vaccine candidate) and Ad26.RSV.FA2 in healthy participants.

Timeline

Start
2015-04-21
Primary completion
2016-06-09
Completion
2016-06-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ad26.RSV.FA2 Vaccine 5e+10 unknown Intramuscular
Subject Ad35.RSV.FA2 Vaccine 1e+11 unknown Intramuscular

Indications

No indication recorded.